Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL

Elizabeth A. Brem, Susan M. O'Brien, Pamela S. Becker, Deepa Jeyakumar, Lauren C. Pinter-Brown, Christina Kirk, Thomas Taylor, Blake Johnson, Stephanie Osorio, Roberta Buono, David A Fruman

Blood (2023) 142 (Supplement 1): 5940.

https://doi.org/10.1182/blood-2023-188086

Published: 2023

Journal Articles

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Blood (2020) 135 (26): 2337–2353.

https://doi.org/10.1182/blood.2020004834

Published: 2020

Includes: Supplemental data

Journal Articles

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

Changchun Deng, Mark R. Lipstein, Luigi Scotto, Xavier O. Jirau Serrano, Michael A. Mangone, Shirong Li, Jeremie Vendome, Yun Hao, Xiaoming Xu, Shi-Xian Deng, Ronald B. Realubit, Nicholas P. Tatonetti, Charles Karan, Suzanne Lentzsch, David A. Fruman, Barry Honig, Donald W. Landry, Owen A. O’Connor

Blood (2017) 129 (1): 88–99.

https://doi.org/10.1182/blood-2016-08-731240

Published: 2017

Includes: Supplemental data

Journal Articles

mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL

Moran Gotesman, MD, Thanh-Trang T Vo, PhD, Sharmila Mallya, MS, Qi Zhang, MDPhD, Ce Shi, MD PhD, Markus Müschen, MD PhD, David M. Weinstock, MD, Charles Mullighan, MBBS, MSc, MD, Sarah K Tasian, MD, Marina Konopleva, MD PhD, David A. Fruman, PhD

Blood (2016) 128 (22): 2763.

https://doi.org/10.1182/blood.V128.22.2763.2763

Published: 2016

Journal Articles

Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma

David A. Fruman, PhD, Jong-Hoon Scott Lee, B.S., Thanh-Trang T Vo, PhD, Shruti Bhatt, PhD, Jonathan H. Schatz, MD, Anthony Letai, MD PhD

Blood (2016) 128 (22): 3969.

https://doi.org/10.1182/blood.V128.22.3969.3969

Published: 2016

Journal Articles

mTOR signaling: new networks for ALL

David A. Fruman

Blood (2016) 127 (22): 2658–2659.

https://doi.org/10.1182/blood-2016-03-703199

Published: 2016

Journal Articles

The Dynamics of Stroma-Leukemia Interaction in the Hypoxic BM Niches in Vivo

Karine G. Harutyunyan, PhD, Felix Nwajei, M. Anna Zal, David A Fruman, PhD, Saradhi Mallampati, PhD, Xiaoping Sun, MD PhD, Tomasz Zal, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 2396.

https://doi.org/10.1182/blood.V124.21.2396.2396

Published: 2014

Journal Articles

Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2 -Rearranged Ph-like Acute Lymphoblastic Leukemia

Ce Shi, Lina Han, PhD, Yoko Tabe, MD PhD, Hong Mu, MD PhD, Shuo-Chieh Wu, Jin Zhou, MD, PhD, Zhihong Zeng, MD, David A Fruman, PhD, Sarah K Tasian, MD, David M. Weinstock, MD, Marina Konopleva, MD PhD

Blood (2014) 124 (21): 3706.

https://doi.org/10.1182/blood.V124.21.3706.3706

Published: 2014

Journal Articles

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

Zhihong Zeng, Yue Xi Shi, Twee Tsao, YiHua Qiu, Steven M. Kornblau, Keith A. Baggerly, Wenbin Liu, Katti Jessen, Yi Liu, Hagop Kantarjian, Christian Rommel, David A. Fruman, Michael Andreeff, Marina Konopleva

Blood (2012) 120 (13): 2679–2689.

https://doi.org/10.1182/blood-2011-11-393934

Published: 2012

Includes: Supplemental data

Journal Articles

The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models

David A Fruman, PhD, Matthew Robert Janes, MPH, Sharmila Mallya, MS, Collin C Vu, MD, Marie P. Shieh, MD, Michael B. Lilly, MD, Leonard S Sender, MD, Michael B Martin, PhD, Pingda Ren, PhD, Yi Liu, PhD, Christian Rommel, PhD

Blood (2011) 118 (21): 2585.

https://doi.org/10.1182/blood.V118.21.2585.2585

Published: 2011

Journal Articles

Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function

Sharon Lim, PhD, Tzuen Yih Saw, Sandy Chang, Min Zhang, MD, Matthew Robert Janes, MPH, David A Fruman, PhD, David A. Rizzieri, MD, Soo-Yong Tan, MBBS, FRCPath, DPhil, Charles Chuah, MD, S. Tiong Ong, MD

Blood (2011) 118 (21): 963.

https://doi.org/10.1182/blood.V118.21.963.963

Published: 2011

Journal Articles

Targeting mTORC1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment

Zhihong Zeng, Yuexi Shi, Twee Tsao, Yihua Qiu, Steven M. Kornblau, MD, Keith Baggerly, Wenbin Liu, Yi Liu, PhD, Christian Rommel, PhD, David A. Fruman, Michael Andreeff, MD, PhD, Marina Konopleva, MD, PhD

Blood (2010) 116 (21): 778.

https://doi.org/10.1182/blood.V116.21.778.778

Published: 2010

Journal Articles

p85β phosphoinositide 3-kinase regulates CD28 coreceptor function

Isabela Alcázar, Isabel Cortés, Angel Zaballos, Carmen Hernandez, David A. Fruman, Domingo F. Barber, Ana C. Carrera

Blood (2009) 113 (14): 3198–3208.

https://doi.org/10.1182/blood-2008-04-152942

Published: 2009

Journal Articles

T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling

Jonathan A. Deane, Michael G. Kharas, Jean S. Oak, Linda N. Stiles, Ji Luo, Travis I. Moore, Hong Ji, Christian Rommel, Lewis C. Cantley, Thomas E. Lane, David A. Fruman

Blood (2006) 109 (7): 2894–2902.

https://doi.org/10.1182/blood-2006-07-038620

Published: 2006

Journal Articles

KLF4 suppresses transformation of pre-B cells by ABL oncogenes

Michael G. Kharas, Isharat Yusuf, Vanessa M. Scarfone, Vincent W. Yang, Julia A. Segre, Claudia S. Huettner, David A. Fruman

Blood (2006) 109 (2): 747–755.

https://doi.org/10.1182/blood-2006-03-011106

Published: 2006

Journal Articles

Bursting with PIP 3

David A. Fruman

Blood (2005) 106 (4): 1139–1140.

https://doi.org/10.1182/blood-2005-05-2040

Published: 2005

Journal Articles

Optimal B-cell proliferation requires phosphoinositide 3-kinase–dependent inactivation of FOXO transcription factors

Isharat Yusuf, Xiaocui Zhu, Michael G. Kharas, Jing Chen, David A. Fruman

Blood (2004) 104 (3): 784–787.

https://doi.org/10.1182/blood-2003-09-3071

Published: 2004

Journal Articles

Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cells

Michael G. Kharas, Jonathan A. Deane, Stephane Wong, Karen R. O'Bosky, Naomi Rosenberg, Owen N. Witte, David A. Fruman

Blood (2004) 103 (11): 4268–4275.

https://doi.org/10.1182/blood-2003-07-2193

Published: 2004

Includes: Supplemental data

NARROW

A Phase 1 Study of Adding Pitavastatin to Venetoclax-Based Therapy in AML and CLL/SLL

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

mTOR Kinase Inhibitors Enhance Efficacy of TKIs in Preclinical Models of Ph-like B-ALL

Statins Potentiate the Cytotoxic Effect of ABT-199 in Diffuse Large B Cell Lymphoma

mTOR signaling: new networks for ALL

The Dynamics of Stroma-Leukemia Interaction in the Hypoxic BM Niches in Vivo

Dual Targeting of JAK2 Signaling with a Type II JAK2 Inhibitor and of mTOR with a TOR Kinase Inhibitor Induces Apoptosis in CRLF2 -Rearranged Ph-like Acute Lymphoblastic Leukemia

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

The TOR Kinase Inhibitor INK128 Is Effective in Pre-B Acute Lymphoblastic Leukemia Models

Targeting of a Novel MNK-eIF4E-b-Catenin Axis in Blast Crisis Chronic Myelogenous Leukemia Inhibits Leukemia Stem Cell Function

Targeting mTORC1/2 by a mTOR Kinase Inhibitor (PP242) induces Apoptosis In AML Cells Under Conditions Mimicking Bone Marrow Microenvironment

p85β phosphoinositide 3-kinase regulates CD28 coreceptor function

T-cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase signaling

KLF4 suppresses transformation of pre-B cells by ABL oncogenes

Bursting with PIP 3

Optimal B-cell proliferation requires phosphoinositide 3-kinase–dependent inactivation of FOXO transcription factors

Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only